Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Unlabelled: Equine hepacivirus (EHCV; nonprimate hepacivirus) is a hepatotropic member of the Flaviviridae family that infects horses. Although EHCV is the closest known relative to hepatitis C virus (HCV), its complete replication kinetics in vivo have not been described, and direct evidence that it causes hepatitis has been lacking. In this study, we detected EHCV in 2 horses that developed post-transfusion hepatitis. Plasma and serum from these horses were used to experimentally transmit EHCV to 4 young adult Arabian horses, two 1-month-old foals (1 Arabian and 1 Arabian-pony cross), and 2 foals (1 Arabian and 1 Arabian-pony cross) with severe combined immunodeficiency (SCID). Our results demonstrated that EHCV had infection kinetics similar to HCV and that infection was associated with acute and chronic liver disease as measured by elevations of liver-specific enzymes and/or by histopathology. Although most of these animals were coinfected with equine pegivirus (EPgV), also a flavivirus, EPgV viral loads were much lower and often undetectable in both liver and blood. Three additional young adult Arabian-pony crosses and 1 SCID foal were then inoculated with plasma containing only EHCV, and evidence of mild hepatocellular damage was observed. The different levels of liver-specific enzyme elevation, hepatic inflammation, and duration of viremia observed during EHCV infection suggested that the magnitude and course of liver disease was mediated by the virus inoculum and/or by host factors, including breed, age, and adaptive immune status.

Conclusion: This work documents the complete infection kinetics and liver pathology associated with acute and chronic EHCV infection in horses and further justifies it as a large animal model for HCV.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.27689DOI Listing

Publication Analysis

Top Keywords

ehcv infection
12
equine hepacivirus
8
hepatitis virus
8
ehcv
8
young adult
8
foals arabian
8
arabian arabian-pony
8
arabian-pony cross
8
infection kinetics
8
associated acute
8

Similar Publications

Article Synopsis
  • Hepaciviruses cause liver disease in horses, with three key viruses (NPHV, TDAV, EPgV) capable of chronic infections.
  • This study aimed to model the NS5B polymerase (an enzyme crucial for viral RNA synthesis) of equine hepaciviruses and assess how well current drugs for hepatitis C (sofosbuvir and dasabuvir) interact with them.
  • The results indicated that sofosbuvir could potentially be effective against equine pathogens, as the interactions of equine NS5B models with it were similar to those seen with HCV-NS5B, while interactions with dasabuvir showed less conservation.
View Article and Find Full Text PDF
Article Synopsis
  • - The 5' untranslated region (UTR) of hepatitis C virus (HCV) is crucial for its translation and replication, while the equine nonprimate hepacivirus (EHcV) also has a similar UTR structure that includes four domains and a pseudoknot.
  • - The study found that the IRES activity of EHcV's 5' UTR is lower than that of HCV, mainly due to differences in domain III, but certain domains from EHcV can functionally replace those in HCV for viral replication.
  • - Unique to EHcV, the region comprising domains I and I' enhances RNA stability and replication independently of microRNA 122 (miR-122
View Article and Find Full Text PDF

International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.

Autoimmun Rev

May 2017

Sorbonne University, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France; INSERM, UMR S 959, Paris, France; CNRS, FRE3632, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology,

Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and studied condition, lymphoma, and neurologic, cardiovascular, endocrine-metabolic or renal diseases. HCV-extrahepatic manifestations (HCV-EHMs) may severely affect the overall prognosis, while viral eradication significantly reduces non-liver related deaths. Different clinical manifestations may coexist in the same patient.

View Article and Find Full Text PDF

Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.

J Hepatol

June 2017

Sorbonne Universités, UPMC Université Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005 Paris, France; INSERM, UMR_S 959, F-75013 Paris, France; CNRS, FRE3632, F-75005 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal

View Article and Find Full Text PDF

International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement.

Autoimmun Rev

December 2016

Sorbonne University, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France; INSERM, UMR S 959, Paris, France; CNRS, FRE3632 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology,

Hepatitis C virus (HCV) infection is responsible for both hepatic and extra-hepatic disorders (HCV-EHDs); these latter are correlated on one hand clearly with HCV lymphotropism causing immune-system dysregulation as well as with viral oncogenic potential, and on the other hand probably with chronic inflammatory status causing cardio-metabolic complications as well as neurocognitive disturbances. The spectrum of HCV-EHDs ranges from mild or moderate manifestations, such as arthralgia, sicca syndrome, peripheral neuropathy, to severe, life-threatening complications, mainly vasculitis and neoplastic conditions. Given the clinical heterogeneity of HCV-EHDs, HCV-infected individuals are inevitably referred to different specialists according to the presenting/prevalent symptom(s); therefore, the availability of comprehensive diagnostic guidelines is necessary for a patient's whole assessment that is decisive for early diagnosis and correct therapeutic approach of various hepatic and HCV-EHDs, regardless of the specific competencies of different physicians or referral centers.

View Article and Find Full Text PDF